Epigenomics AG Reports Financial Results for Fiscal Year 2006
March 30, 2007 02:44 ET
|
Epigenomics AG
* Financials in line with latest expectations:
- Full year revenue EUR 3.5 million, EBIT at EUR -15.8 million
- Operational costs EUR 21.2 million
- Liquidity of EUR 17.3 million as of...
Epigenomics AG to Host Press Conference and Analyst Meeting for 2006 Annual Results
March 22, 2007 06:19 ET
|
Epigenomics AG
BERLIN, Germany and SEATTLE, March 22, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, will hold its annual press...
Epigenomics AG: Clinical Data Show That Colon Polyps Can be Detected With Simple Blood Test
March 20, 2007 03:41 ET
|
Epigenomics AG
BERLIN and SEATTLE, March 20, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company, announced that Prof. Dr. Matthias Ebert, gastroenterologist at the...
Epigenomics AG: Heino Von Prondzynski to Stand for Election Into Supervisory Board
March 05, 2007 02:37 ET
|
Epigenomics AG
BERLIN and SEATTLE, March 5, 2007 (PRIME NEWSWIRE) -- At its meeting on March 1st, the Supervisory Board of Epigenomics AG (Frankfurt:ECX) decided to propose Heino von Prondzynski for election to the...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Board of Directors: Epigenomics AG Appoints Senior Abbott-Executive Geert Walther Nygaard as New CEO
January 16, 2007 02:53 ET
|
Epigenomics AG
BERLIN and SEATTLE, Jan. 16, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) today announced that its Supervisory Board has unanimously decided to appoint Geert Walther Nygaard as the...
Epigenomics AG to Discover Biomarkers in R&D Collaboration With Centocor Inc.
January 04, 2007 02:47 ET
|
Epigenomics AG
BERLIN, Germany, Jan. 4, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), (Other OTC:EPGNF) has entered into an R&D collaboration with Centocor Inc., a US-based, biomedicines company, to...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Contract: Epigenomics AG: Epigenomics AG Reviews All Options for the Commercialization of Cancer Screening Test Products After End of Collaboration With Roche Diagnostics
December 15, 2006 03:05 ET
|
Epigenomics AG
-- Roche Diagnostics notified Epigenomics about the termination of the
joint collaboration on screening tests for early detection of cancer
and returns licensed marker Septin 9
--...
Epigenomics AG: PITX2 Prostate Cancer Molecular Classification Test Successfully Transferred to Affymetrix Diagnostic Platform
December 12, 2006 03:25 ET
|
Epigenomics AG
-- Concordance study demonstrated excellent agreement between
Epigenomics' chosen commercial diagnostic test platform and
prototype research assays.
-- Based on a prior FDA Early...
Epigenomics AG Reports Third Quarter 2006 Results
November 02, 2006 02:44 ET
|
Epigenomics AG
-- Business Fundamentals and Product Development well on Track
-- Search for CEO under way - completion expected by year-end
-- Cash position in line with guidance; revenue and earnings
...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Misc. Strategic Decisions: Epigenomics AG: Focus on Late Stage Product Development
October 26, 2006 02:24 ET
|
Epigenomics AG
-- Berlin Operations Streamlined -- Workforce Reduced by 34 Positions
-- Business Strategy Unchanged -- Focus on Key Value Drivers
BERLIN and SEATTLE, Oct. 26, 2006 (PRIMEZONE) -- Epigenomics...